Merck & Co., Inc. (MRK) — closed signal from September 28, 2025
Target reached Published before the outcome was known, scored automatically when the window closed on December 27, 2025.
Predicted vs. what happened
What happened
Reached its target in 3 days.
The thesis — published September 28, 2025
Merck just won U.S. approval for an easier, under the skin version of KEYTRUDA for 38 tumor types. That should make treatment simpler and help uptake soon. The share price is pushed down, and after news like this it often works back toward its recent average price. Trading has been strong, with lots more people buying than usual. With a supportive market mood, buying in steps targets a 3 month rebound.
Primary drivers
- New easier KEYTRUDA shot approved, likely speeding use across many tumors
- Share price is beaten down, creating room for a near term bounce
- Stronger trading interest than usual points to healthier demand
- Healthcare stocks favored when markets wobble, aiding steady demand
How it played out
MRK: target reached in 3 days
Lyra published MRK at 77.89 on September 28, 2025, with 14% expected growth over a short-term window. The thesis pointed to U.S. approval for an easier under the skin version of KEYTRUDA across 38 tumor types, a beaten down share price, stronger trading interest than usual, and steady healthcare demand when markets wobbled.
Inside the window, MRK reached the 88.05 target in 3 days. It later peaked at 107.05 on December 26, 2025, with a 37.4% peak gain. The window ended at 106.78. The published thesis played out clearly.
What happened during the window
On October 30, 2025, Merck reported third-quarter 2025 results. Investors.com reported sales of $17.28 billion and adjusted earnings per share of $2.58. On November 14, 2025, Investors.com reported that Merck agreed to buy Cidara Therapeutics for $9.2 billion.
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Share this receipt
A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.